Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 2: second line drugs.
about
Kinetic mechanism and inhibition of Mycobacterium tuberculosis D-alanine:D-alanine ligase by the antibiotic D-cycloserineFactors associated with anti-tuberculosis medication adverse effects: a case-control study in Lima, PeruWhat is the cost of diagnosis and management of drug resistant tuberculosis in South Africa?A randomized placebo-controlled pilot study of the efficacy and safety of D-cycloserine in people with chronic back pain.Evaluation of pseudopteroxazole and pseudopterosin derivatives against Mycobacterium tuberculosis and other pathogens.Thyroid function in multidrug-resistant tuberculosis patients with or without human immunodeficiency virus (HIV) infection before commencement of MDR-TB drug regimen.Antimycobacterial drugs currently in Phase II clinical trials and preclinical phase for tuberculosis treatment.Anti-tuberculosis drugs adverse reactions: a review of the Iranian literature.Role of therapeutic drug monitoring in pulmonary infections: use and potential for expanded use of dried blood spot samples.Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis.Repurposing drugs for treatment of tuberculosis: a role for non-steroidal anti-inflammatory drugs.Poncet's disease after the intravesical instillation of Bacillus Calmette-Guérin (BCG): a case report.Pre-harvest cane burning and health: the association between school absences and burning sugarcane fields.Concomitant prescription of oral fluoroquinolones with an antacid preparation.Pharmacokinetics of sequential doses of capreomycin powder for inhalation in guinea pigsVolatile compounds of Lamiaceae exhibit a synergistic antibacterial activity with streptomycin.Evaluation of para-Aminosalicylic Acid as a Substrate of Multiple Solute Carrier Uptake Transporters and Possible Drug Interactions with Nonsteroidal Anti-inflammatory Drugs In Vitro.Enhancement of the antimycobacterial activity of macrophages by ajoene.Pharmacokinetics of Ethionamide Delivered in Spray-Dried Microparticles to the Lungs of Guinea Pigs.Prediction of Antitubercular Peptides From Sequence Information Using Ensemble Classifier and Hybrid Features
P2860
Q28282522-9946F895-4100-4D38-A5F7-C40014553770Q28478014-95899C1C-E887-4980-BFFA-A3D781D25A00Q28485194-FFC34DE9-AAB8-4D3F-9EAF-D6B0B49816F9Q30275402-2CC13821-26ED-4EBF-BA68-FFD69807DAFBQ36248387-91F1266D-9DC8-405B-B577-487F3E4CC26AQ37196818-996AA349-FB31-4E16-B329-81757E13BAB6Q38044744-A9516204-D7CC-4CD8-8E39-A91586F93CF8Q38220765-200ABC01-21DA-4E42-B5F4-8856FC31AA6DQ38369608-B96F630C-9A73-4CB5-A231-9B3F17B8DD6DQ38763608-DA99EDB5-1C7C-4B2D-97F3-47EA4BC6CA99Q38827332-3954338D-CB66-433E-982D-8D9800C68585Q40042737-324AF089-855F-4070-90CE-AFFAA32EFFD3Q40895732-AE9EA5E8-5624-4D81-B02D-1D197E9D7E59Q41347294-2B6444C2-1DB0-42AD-9286-7087BADEAA34Q42151625-9F98782D-63F7-45E4-836F-648DBAD2495EQ42174362-36E155EC-92EF-4605-9A21-326B1DD5C394Q42358808-F0CE9171-E360-4868-B55C-4B97A04E7DAEQ46241400-EC37714E-81F6-4511-907A-DF9C99166FD5Q46271797-038B81C2-E6F4-4A90-8C19-1DDD984F731BQ57319273-D780B349-0698-4ABE-96EB-B95DF0540698
P2860
Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 2: second line drugs.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antituberculosis drugs: drug i ...... ns. Part 2: second line drugs.
@en
Antituberculosis drugs: drug i ...... ns. Part 2: second line drugs.
@nl
type
label
Antituberculosis drugs: drug i ...... ns. Part 2: second line drugs.
@en
Antituberculosis drugs: drug i ...... ns. Part 2: second line drugs.
@nl
prefLabel
Antituberculosis drugs: drug i ...... ns. Part 2: second line drugs.
@en
Antituberculosis drugs: drug i ...... ns. Part 2: second line drugs.
@nl
P2093
P2860
P1476
Antituberculosis drugs: drug i ...... ns. Part 2: second line drugs.
@en
P2093
Fernando Augusto Fiúza de Mello
Hélio Ribeiro de Siqueira
Marcos Abdo Arbex
Marília de Castro Lima Varella
P2860
P304
P356
10.1590/S1806-37132010000500017
P577
2010-09-01T00:00:00Z